PFE
Pfizer Inc.
NYSE
Healthcare
$27.86
+0.12
(+0.41%)
Updated: 3/31/2026, 4:00:01 PM
Open
$27.99
High
$28.30
Low
$27.71
Prev Close
$27.77
Volume
18.08M
Price History
Why Is PFE ▲ Up Today?
+0.41%
Full AI analysis generates after market close. Showing live price data.
Mar 31
▲
+0.4%
Pfizer (PFE) Up Slightly Amidst Positive Data and Market Attention
Mar 30
▲
+2.3%
Pfizer (PFE) Rises on GLP-1 Program Interest and Positive Sentiment
Mar 27
▼
-1.9%
Pfizer (PFE) Down Slightly Amid Mixed News
Mar 26
▲
+1.1%
Pfizer (PFE) Climbs on Promising Pipeline and Analyst Optimism
Mar 25
▲
+1.3%
Pfizer (PFE) Rises on Analyst Optimism and Pipeline Progress
Mar 24
▲
+0.9%
Pfizer (PFE) Up Slightly Amid Positive Sector Sentiment and Company-Specific News
Mar 23
▼
-0.6%
Pfizer (PFE) dips slightly following mixed Lyme vaccine data
Mar 20
▼
-1.9%
Pfizer (PFE) Down Slightly Amidst Mixed Sector Performance
Mar 19
▲
+0.5%
Pfizer (PFE) Up Slightly Amidst Positive Clinical Trial News
Mar 18
▼
-0.8%
Pfizer (PFE) Down Slightly Amidst Mixed News, Outperforming Healthcare Sector
Mar 17
▲
+3.4%
Pfizer (PFE) Up 3.38% on Positive Breast Cancer Data
Mar 16
▲
+0.2%
Pfizer (PFE) Up Slightly Amid Mixed Healthcare Sector News
Mar 13
▼
-1.0%
Pfizer (PFE) Down Slightly Amidst Mixed Sentiment
Mar 12
▼
-1.5%
Pfizer (PFE) Declines Amid Sector Weakness and Investor Concerns
Mar 11
▲
+0.3%
Pfizer (PFE) modestly up amid sector gains
Mar 10
▲
+0.6%
Pfizer (PFE) Rises Slightly Following Positive Phase 2 Eczema Drug Trial
Mar 9
▼
-1.1%
Pfizer (PFE) Down Slightly Despite Positive Drug Data
Mar 6
▲
+1.3%
Pfizer (PFE) Rises on China Weight-Loss Drug Approval
Mar 5
▼
-0.2%
Pfizer (PFE) Down Slightly Amidst Sector Weakness
Mar 4
▲
+0.2%
Pfizer (PFE) modestly up amid sector gains and GLP-1 market optimism
Mar 3
▼
-2.3%
Pfizer (PFE) Down 2.25% Amidst Mixed Industry News
Mar 2
▼
-1.6%
Pfizer (PFE) dips slightly amid sector weakness.
Feb 27
▲
+1.8%
Pfizer (PFE) Rises Slightly Amidst Sector Gains
Feb 26
—
+0.0%
Pfizer (PFE) edges up amid sector decline, FDA nod for colorectal cancer drug
Feb 25
▼
-0.4%
Pfizer (PFE) dips slightly despite positive FDA approval, mixed analyst sentiment
Feb 24
—
+0.0%
Pfizer (PFE) Stays Flat Amid Sector Decline
Feb 23
▲
+1.5%
Pfizer (PFE) Rises Slightly Amidst Sector Gains
Feb 20
▼
-1.0%
Pfizer (PFE) Down Slightly Amidst Mixed Sector News
Feb 19
▼
-2.4%
Pfizer (PFE) down 2.37% amid mixed sector performance.
Feb 18
▼
-0.2%
PFE falls 0.2%
Financial Highlights
Income Statement
Revenue
$62.78B
Gross Profit
$46.08B
73.4% margin
Operating Income
$9.15B
14.6% margin
Net Income
$9.87B
15.7% margin
EPS (Diluted)
$1.72
Balance Sheet
Total Assets
$208.73B
Total Liabilities
$115.64B
Stockholders' Equity
$93.10B
Cash Flow
Operating Cash Flow
$13.08B
Investing Activities
$3.17B
Net Cash Flow
$242.0M
Highly Regarded Analysis for PFE
Get a deep-dive analysis including bull/bear cases, technical outlook, price targets, and key catalysts — powered by Highly Regarded's proprietary analysis engine.
Usually takes 10-20 seconds
Analyzing PFE...
Searching financial data and generating insights
Analysis couldn't be generated
Key Stats
P/E Ratio
16.2x
EPS (Diluted)
$1.72
Gross Margin
73.4%
Operating Margin
14.6%
Net Margin
15.7%
Revenue (Qtr)
$62.78B
Shares Outstanding
5.69B
Next Earnings
Date
Aug 4, 2026
Time
TBD
Quarter
Q2 2026
EPS Estimate
$0.68
PFE News
No recent news for PFE.